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Background  and  purpose:  The  purpose  of  the present  study  was to examine  the  mid-term  clinical  and
angiographic  outcomes  of  patients  with  ST-segment  elevation  myocardial  infarction  (STEMI)  who  pre-
sented within  48  h and  received  paclitaxel-eluting  stents  (PES)  or sirolimus-eluting  stents  (SES).
Methods  and results:  This  study  was  a retrospective,  non-randomized,  single-center  study.  The  post-
discharge  clinical  outcomes  of  357  consecutive  patients  who  presented  within  48 h of their  ﬁrst  STEMI
and  received  PES  (n = 163)  or SES  (n = 194)  between  February  2007  and  February  2009  were  analyzed  in
May 2011.  The  incidence  of post-discharge  events  (i.e.  cardiac  death  and  non-fatal  recurrent  MI)  after  PES
placement (0.6%)  did  not  signiﬁcantly  differ  from  that  after  SES  placement  (1.5%).  Treatment  with  PES
was not  related  to the  risk  of adverse  events  post-discharge  (mean  follow-up  period  for PES  placement,
1170  ± 243  days;  hazard  ratio,  0.346;  95%  CI,  0.036–3.371;  p  =  0.361).  No deﬁnite  stent  thromboses  devel-
oped  after  treatment  with  PES  or SES.  The  incidence  of  binary  in-stent  restenosis  (stenosis  of more  than
50% of  the  diameter  at secondary  angiography  performed  10–18  months  after  the  initial  procedure)  after
PES placement  (17.1%)  was  signiﬁcantly  higher  than  that after  SES placement  (4.8%;  p < 0.001).  PES place-
ment  was  an  independent  predictor  of  binary  in-stent  restenosis  (odds  ratio,  3.892;  95%  CI, 1.470–10.30;
p  =  0.006).
Conclusions:  Retrospective  examination  of the  post-discharge  clinical  course  after  placement  of  PES and
SES showed  favorable  midterm  clinical  outcomes  among  Japanese  STEMI  patients  treated  within  48  h of
onset. However,  SES  treatment  resulted  in  superior  angiographic  outcomes  compared  to  PES.
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. Introduction
Previous reports have conﬁrmed the mid-term safety and efﬁ-
acy of primary stenting using sirolimus-eluting stents (SES) in
apanese patients with ST-segment elevation myocardial infarction
STEMI) [1,2]. However, the safety and efﬁcacy of paclitaxel-eluting
tents (PES), drug-eluting stents (DES) approved for clinical use
n Japan in May  2007, for STEMI patients are not well charac-
erized in Japan. Therefore, it is important to compare the safety
nd efﬁcacy of PES in the treatment of STEMI, including high-
isk STEMI, to those of SES. This is particularly important for
atients in Japan, where the incidence of cardiac events, such as
∗ Corresponding author at: 1696 Itai, Kumagaya, Saitama 360-0105, Japan. Tel.:
81 485 36 9900x2250; fax: +81 485 36 9920.
E-mail addresses: ishikawa.tetsuya@pref.saitama.lg.jp,
ecchanis250@gmail.com (T. Ishikawa).
914-5087/$ – see front matter © 2012 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jjcc.2012.03.009anese  College  of Cardiology.  Published  by  Elsevier  Ltd.  All rights  reserved.
stent thrombosis (ST) [3],  is lower than that in western countries
[1,4–6].
The beneﬁts of late reperfusion (12–48 h after MI  onset) have
been established in clinical and experimental trials [7].  However,
the safety and efﬁcacy of DES use for the treatment of patients
with STEMI patients presented within 48 h after MI  onset have
not been fully examined in Japan [8]. Further, the impact of late
reperfusion by percutaneous coronary intervention (PCI) for STEMI
patients, including asymptomatic patients and those with stable
hemodynamic states, remains debatable [7–9].
Therefore, we  retrospectively examined the mid-term post-
discharge clinical and angiographic outcomes of 357 consecutive
STEMI patients presenting within 48 h and treated with either PES
or SES in a clinical setting. We  compared the incidences of (A)
post-discharge cardiac events, including cardiac death and nonfatal
recurrent MI  (re-MI), as the safety endpoints and (B) angiographic
binary in-stent restenosis [more than 50% diameter stenosis (DS)
in the follow-up angiogram (fu CAG)] as the efﬁcacy endpoint.
vier Ltd. All rights reserved.
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Table 1
Baseline characteristics of 357 patients who underwent primary stenting with PES
or SES and were alive at discharge.
PES SES p-Value
n 163 194
Age (years) 64.1 ± 11.9 65.7 ± 11.2 0.190
Male gender (%) 82.8 79.4 0.410
Diabetes (%) 38.0 34.0 0.430
Cardiac dysfunction (%) 17.2 27.8 0.036
Elapsed time ≤ 12 h (%) 85.9 84.9 0.720
Killip classiﬁcation 1.27 ± 0.76 1.34 ± 0.78 0.390
First TIMI-grade 2–3 ﬂow (%) 35.0 35.1 0.990
Rentrop grade 2–3 (%) 19.0 17.5 0.720
Single-vessel disease (%) 40.5 52.1 0.029
LAD (%) 42.9 52.1 0.085
RCA (%) 47.2 33.0 <0.01
Calciﬁcation (%) 6.1 3.6 0.260
Bifurcation (%) 42.9 36.6 0.220
Thrombus (%) 19.6 10.8 0.020
Number of stents 1.44 ± 0.65 1.30 ± 0.48 0.023
Diameter of stent (mm) 3.27 ± 0.43 3.32 ± 0.48 0.300
Length of stent (mm) 35.0 ± 16.4 32.2 ± 14.6 0.100
Maximum pressure (atm) 18.0 ± 2.9 19.1 ± 2.7 <0.001
IVUS use (atm) 96.3 97.4 0.550
Distal protection (%) 71.2 74.2 0.520
Thrombectomy (%) 74.2 74.2 1.000
Final TIMI-grade 2–3 ﬂow (%) 96.9 99.5 0.060
Pre-procedure
MLD  (mm)  0.337 ± 0.464 0.336 ± 0.506 0.980
%  Diameter stenosis 87.9 ± 15.9 88.0 ± 17.8 0.960
Post-procedure
MLD  (mm)  2.58 ± 0.459 2.57 ± 0.457 0.840
%  Diameter stenosis 13.6 ± 9.4 12.8 ± 9.4 0.420
Reference diameter (mm) 3.00 ± 0.569 2.97 ± 0.569 0.620
Acute gain (mm) 2.23 ± 0.635 2.23 ± 0.621 1.000
Medication at discharge
-Blocker (%) 80.4 78.9 0.730
ACE-I/ARB (%) 85.9 91.8 0.077
Statin (%) 87.7 87.6 0.980
Total endpoint (n, %) 1, 0.6 3, 1.5 0.400
Cardiac death (n, %) 1, 0.6 3, 1.5 0.400
Non-fatal re-MI (n, %) 0 0
Post-discharge observation
duration (days)
1170 ± 243 1148 ± 283 0.430
Variables related to patients, clinical condition, lesions, procedure, medication at
discharge, and endpoint are shown. Deﬁnitions of abbreviations are provided in the
The safety endpoints of the clinical outcomes were (A)T. Ishikawa et al. / Journal o
. Methods
.1. Population
The rationale of the almost unrestricted use of DESs, includ-
ng their use in STEMI patients, has been previously reported
1,4,6].  From February 2007 to February 2009, the period prior
o the approval of PES (TAXUS Liberte) for clinical use in Japan,
69 patients presenting within 48 h of their ﬁrst STEMI and with-
ut prior coronary artery bypass grafts (CABG) were treated using
ES; 198 were treated with SES, and 25 were treated with bare-
etal stents. DESs were used in 93.6% of the cases. The incidence of
n-hospital mortality after PES placement (n = 6, 3.6%) did not signif-
cantly differ from that after SES placement (n = 4, 2.0%) (p = 0.37). Of
he 10 cases of in-hospital mortality, 6 deaths were due to cardio-
enic shock and severe congestive heart failure (Killip class 3–4,
eﬁned below), 2 were caused by cardiac rupture, and 2 were
aused by pneumonia. None of the cases matched the criteria for
T as deﬁned by the Academic Research Consortium [3].  In May
011, the clinical and angiographic outcomes in patients who  were
live at discharge after treatment with PES (n = 163) were com-
ared with those of patients who underwent treatment with SES
n = 194), as in our previous report [1].  Angiographic outcomes in
he fu CAG until May  2011 were included. An additional fu CAG
as planned approximately 10–18 months after stent placement
nd was performed in 75.5% (123/163) of PES patients and 75.8%
147/194) of SES patients (no signiﬁcant difference). All patients
ere encouraged to undergo optimal medical therapy according
o the guidelines for the management and prevention of sec-
ndary MI  (Table 1), as outlined by the Japanese Circulation Society
10].
.2. Procedures for stenting and antiplatelet therapy
The device used to restore coronary ﬂow was selected based
n the doctor’s discretion. Therefore, this was a non-randomized
tudy. Stents were implanted to cover the entire baseline lesion,
nd implantation was performed under the guidance of intravas-
ular ultrasonography (IVUS-guide). When additional stent dilation
as needed, high-pressure ballooning using a non-compliant bal-
oon was performed. Because lesions after STEMI may  develop
ue to slow or no reﬂow, a distal protection method using
he PercuSurge GuardWire® (Medtronic, Santa Rosa, CA, USA)
evice in combination with a thrombosuction catheter was
referred.
Peri-procedural antiplatelet therapy was administered, as
reviously reported [1,4,6].  At the emergency care unit, before per-
orming PCI, aspirin (162–200 mg)  and ticlopidine (200 mg)  were
mmediately administered orally. Although these prescriptions
ere not prospectively randomized, ticlopidine was  prescribed
or about 1 year in accordance with the recommended guide-
ines. Cilostazol (200–300 mg/day) or clopidogrel (75 mg/day) were
dministered at the doctor’s discretion if ticlopidine administration
howed adverse effects.
.3. Follow-up angiography and quantitative coronary artery
ngiography
The time points at which fu CAG was performed are pro-
ided above. The quantitative coronary artery angiography (QCA)
arameters were measured using the test circulatory system car-
iovascular network system, as described previously [1,8]; their
alues were obtained at 3 points: before PCI (pre-procedural);
mmediately after successful PCI (post-procedural); and during the
hronic phase (follow-up) (CAAS II system; Pie Medical, Maas-
richt, The Netherlands). The minimal lumen diameter (MLD),text.
%DS, reference diameter, and lesion length were also measured.
In cases showing occlusion thrombolysis in myocardial infarc-
tion (TIMI) grade 0–1 ﬂow, pre-procedural MLD  was  considered
as 0, and %DS was  considered as 100. In addition, acute lumi-
nal gain (post-procedural MLD  minus pre-procedural MLD) and
late luminal loss (post-procedural MLD  minus MLD  during the
chronic phase) were calculated. Binary in-stent restenosis (binary
restenosis) was  deﬁned as %DS of <50% during the chronic phase.
Target lesion revascularization (TLR) observed on the fu CAG was
deﬁned as elective or emergency repeated PCI or CABG, including
in-stent restonosis, performed at the 5-mm proximal and distal
stent margins [11]. The need for TLR was  determined based on
visual angiographic outcomes. The percentage of severe restenosis
(%DS ≥ 70%) was  estimated.
2.4. Endpointspost-discharge events including death and excluding deﬁnite non-
cardiac death and nonfatal re-MI. The efﬁcacy endpoint of the
angiographic outcome was (B) the incidence of binary restenosis
(deﬁned above).
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.5. Estimated variables
The variables used as baseline characteristics (patient data,
linical characteristics, lesion characteristics, and procedure at dis-
harge) were deﬁned as follows: age (age at stenting); male gender;
iabetes (patients with diabetes mellitus); elapsed time within 12 h
if the interval between STEMI onset and hospital arrival was within
2 h); Killip classiﬁcation; cardiac dysfunction (ejection fraction of
eft ventricle less than 40% as evaluated by ultrasonography or left
entriculogram); ﬁrst TIMI grade 2–3 ﬂow (TIMI-grade 2 or 3 ﬂow
t the ﬁrst angiogram); Rentrop grade 2–3 (Rentrop grade 2 or 3
or collateral ﬂow); single-vessel disease (only 1 diseased vessel of
he native coronary artery); location of the culprit lesion in the left
nterior descending artery (LAD) and right coronary artery (RCA);
alciﬁcation (calciﬁed lesions estimated using an angiogram and
VUS); bifurcation (bifurcative lesions requiring any treatment of
he side branch); thrombus (thrombus-containing lesion); num-
er of stents (number of implanted stents per lesion); diameter
f stents (maximum diameter of the balloon used to dilate the
tent); length of stent (length of the stented segment, calculated by
dding the lengths of each stent regardless of overlap); maximum
ressure (maximum pressure at the maximum diameter of the
nﬂated balloon); IVUS use (availability of IVUS during PCI); distal
rotection (lesions treated with the PercuSurge GuardWire device
r ﬁlter wire); thrombectomy (performing thrombectomy using
ny thrombosuction catheter); ﬁnal TIMI grade 2–3 ﬂow (post-
rocedural TIMI grade 2 or 3 ﬂow); post-discharge observational
eriod (duration in days monitored after discharge); medications
t discharge: -blocker (beta-adrenergic blockers); ACE-I/ARB
angiotensin-converting enzyme inhibitors or angiotensin receptor
lockers); statins (HMG-CoA reductase inhibitors). The lesion loca-
ion, calciﬁcation, bifurcation, and thrombus variables were deﬁned
ccording to the American College of Cardiology/American Heart
ssociation classiﬁcation of lesions.
.6. Statistics
Baseline characteristics were expressed as mean ± standard
eviation (SD). The PES and SES group variables (at both base-
ine and angiographic follow-up) were compared using unpaired
-tests for continuous values and 2 tests or Fisher’s exact tests
or categorical values. The present study compared the safety and
fﬁcacy between SES and PES. Therefore, the following steps were
erformed in order to create a multivariate model: (a) clinical and
ngiographic variables were compared between endpoint-positive
nd endpoint-negative groups, and p-values for each comparison
ere calculated using 2 test, Fisher’s exact test, or t test (uni-
ariate analysis). (b) Multivariate analysis for predicting adverse
afety and efﬁcacy endpoints was performed; stent type (PES) was
ncluded as an independent variable, and other variables found
o be signiﬁcant in the univariate analysis were added. The Cox
roportional hazard model was used by only including 1 vari-
ble (PES) in order to analyze the predictors of post-discharge
vents, because there were no signiﬁcant differences between the
atients with and without cardiac events in terms of baseline or
esion characteristics. Predictors of binary restenosis were analyzed
sing a logistic regression analysis by including 7 variables (ﬁrst
IMI-grade 2–3 ﬂow, calciﬁcation, PES, number of stents, length
f stent, pre-procedural MLD, and pre-procedural %DS) (Table 4).
n order to compare the properties of PES and SES, the predic-
ors of binary in-stent restenosis were individually analyzed in
he PES and SES groups, as described above. A p-value less than
.05 was considered statistically signiﬁcant. Stata for Windows ver-
ion 8 (StataCorp, College Station, TX, USA) was used for statistical
nalysis.iology 60 (2012) 174–179
3. Results
3.1. Baseline characteristics of patients who were alive at
discharge
Table 1 shows the baseline characteristics of patients receiving
primary stenting with PES (n = 163) and SES (n = 194). The per-
centages of cardiac dysfunction, single-vessel disease, RCA lesions,
thrombus, number of stents, and maximum pressure signiﬁcantly
differed between the PES and SES groups. Baseline QCA, percent-
age of primary endpoints, and the post-discharge observational
duration did not signiﬁcantly differ between the groups.
3.2. Predictors of primary endpoint after discharge
When the baseline characteristics of patients who  had cardiac
events (n = 4) were compared with those without cardiac events
after discharge (n = 353), there were no signiﬁcant differences
between the groups in terms of baseline or lesion characteristics
(data not shown). Four patients died due to severe congestive heart
failure without ST [3].
Using the Cox proportional hazard model, PES was not found to
be related to post-discharge endpoints (hazard ratio, 0.346; 95% CI,
0.036–3.371; p = 0.361).
3.3. Baseline characteristics of patients and angiographic
outcomes in fu CAG
Table 2 shows the baseline characteristics of patients in fu CAG
and the results from the serial QCA after performing fu CAG. The
percentage of single-vessel disease, mean number of stents, and
maximum pressure were signiﬁcantly different between the PES
(n = 123) and SES (n = 147) groups. In addition, 3 variables from
the follow-up QCA data signiﬁcantly differed between the groups.
There was signiﬁcantly greater late luminal loss in the PES group
than in the SES group. The incidences of binary restenosis, severe
restenosis, and TLR were signiﬁcantly higher in the PES group than
in the SES group.
3.4. Baseline characteristics and angiographic outcomes of
patients with and without binary restenosis
Table 3 shows the baseline characteristics of patients in fu CAG
and the results from the serial QCA after performing fu CAG. The
percentage of ﬁrst TIMI-grade 2–3 ﬂow, calciﬁcation, PES, mean
number of stents, and mean length of stents were signiﬁcantly
different between those with binary restenosis (n = 28) and those
without binary restenosis (n = 242). Two  pre-procedural variables, 4
follow-up QCA variables, and late luminal loss differed signiﬁcantly
between the groups. The incidences of binary restenosis, severe
restenosis, and TLR and the mean angiographic follow-up dura-
tion signiﬁcantly differed between those with and without binary
restenosis.
3.5. Predictors of binary restenosis after treatment with PES or
SES for STEMI presenting within 48 h of onset
Table 4 shows the predictors of binary restenosis, which were
identiﬁed using a logistic regression analysis. In the multivariate
analysis, PES was  the single predictor of binary restenosis in 270
STEMI patients after performing primary stenting with PES or SES.
The length of the stent, calciﬁcation, pre-procedural %DS, number
of stents, ﬁrst TIMI-grade 2–3 ﬂow, and pre-procedural MLD  were
not signiﬁcant predictors of binary restenosis.
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Table  2
Baseline characteristics and serial quantitative coronary angiography ﬁndings after
follow-up secondary angiography in 270 patients who underwent primary stenting
with PES or SES.
PES SES p-Value
n 123 147
Age (years) 62.9 ± 10.8 64.2 ± 10.2 0.310
Male gender (%) 87.0 81.0 0.180
Diabetes (%) 42.3 34.7 0.200
Cardiac dysfunction (%) 18.7 27.9 0.077
Elapsed time ≤ 12 h (%) 85.9 84.9 0.620
Killip classiﬁcation 3–4 (%) 8.9 6.8 0.510
First  TIMI-grade 2–3 ﬂow (%) 35.0 29.9 0.378
Rentrop grade 2–3 (%) 19.5 21.1 0.748
Single-vessel disease (%) 43.1 57.1 0.021
LAD  (%) 46.3 53.7 0.230
RCA  (%) 43.9 32.7 0.058
Calciﬁcation (%) 5.7 2.0 0.110
Bifurcation (%) 43.9 36.1 0.190
Thrombus (%) 18.7 12.9 0.190
Number of stents 1.50 ± 0.65 1.32 ± 0.54 0.014
Diameter of stent (mm)  3.27 ± 0.41 3.33 ± 0.48 0.270
Length of stent (mm) 36.3 ± 17.3 32.8 ± 15.0 0.080
Maximum pressure (atm) 18.2 ± 2.9 19.2 ± 2.5 <0.01
IVUS use (atm) 95.9 98.0 0.329
Distal protection (%) 71.5 77.6 0.260
Thrombectomy (%) 76.4 78.2 0.730
Final TIMI-grade 2–3 ﬂow (%) 97.6 99.3 0.220
Pre-procedure
MLD (mm) 0.334 ± 0.471 0.283 ± 0.471 0.380
%  Diameter stenosis 88.4 ± 15.6 90.2 ± 15.8 0.350
Post-procedure
MLD (mm) 2.58 ± 0.457 2.58 ± 0.446 1.000
%  Diameter stenosis 14.5 ± 9.7 12.7 ± 9.1 0.120
Reference diameter (mm) 3.03 ± 0.553 2.97 ± 0.553 0.370
Follow-up
MLD (mm) 2.19 ± 0.820 2.48 ± 0.652 <0.01
%  Diameter stenosis 29.2 ± 21.7 22.0 ± 15.2 <0.01
Reference diameter (mm)  3.07 ± 0.563 3.17 ± 0.554 0.140
Lesion length (mm) 6.13 ± 4.02 5.10 ± 3.59 0.028
Acute gain (mm)  2.24 ± 0.616 2.29 ± 0.595 0.499
Late  luminal loss (mm) 0.382 ± 0.789 0.094 ± 0.513 <0.001
Medication at discharge
-Blocker (%) 82.9 85.7 0.530
ACE-I/ARB (%) 91.9 93.2 0.680
Statin (%) 93.5 92.5 0.750
Binary restenosis (%) 17.1 4.8 <0.001
Follow-up %DS ≥ 70 (%) 7.3 2.0 0.036
TLR  (%) 18.7 6.8 <0.01
Angiographic follow-up
duration (days)
432± 221 430± 211 0.940
Variables related to patients, clinical condition, lesions, and procedure, and the
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Table 3
Baseline characteristics and serial quantitative coronary angiography ﬁndings after
follow-up secondary angiography of patients with or without binary restenosis after
underwent primary stenting with PES or SES.
Binary
restenosis
No binary
restenosis
p-Value
n 28 242
Age (years) 63.4 ± 9.52 63.6 ± 10.6 0.917
Male gender (%) 85.7 83.5 0.761
Diabetes (%) 53.6 36.4 0.076
Cardiac dysfunction (%) 32.1 22.7 0.267
Elapsed time ≤ 12 h (%) 75.0 86.0 0.126
Killip classiﬁcation 3–4 (%) 7.1 7.9 0.895
First TIMI-grade 2–3 ﬂow (%) 14.3 34.3 0.032
Rentrop grade 2–3 (%) 25.0 19.8 0.521
Single-vessel disease (%) 39.3 52.1 0.200
LAD (%) 53.6 50.0 0.720
RCA (%) 32.1 38.4 0.516
Calciﬁcation (%) 10.7 2.9 0.038
Bifurcation (%) 42.9 39.3 0.712
Thrombus (%) 25.0 14.5 0.145
PES  (%) 75.0 42.1 <0.001
Number of stents 2.00 ± 0.816 1.34 ± 0.561 <0.001
Diameter of stent (mm) 3.19 ± 0.488 3.31 ± 0.444 0.214
Length of stent (mm) 50.8 ± 20.3 32.5 ± 14.5 <0.001
Maximum pressure (atm) 18.2 ± 2.79 18.8 ± 2.76 0.281
IVUS use (atm) 92.9 97.5 0.168
Distal protection (%) 85.7 73.6 0.160
Thrombectomy (%) 78.6 77.3 0.876
Final TIMI-grade 2–3 ﬂow (%) 96.4 98.8 0.334
Pre-procedure
MLD  (mm)  0.100 ± 0.257 0.330 ± 0.484 <0.001
%  Diameter stenosis 96.3 ± 9.80 88.5 ± 16.0 <0.001
Post-procedure
MLD  (mm) 2.55 ± 0.442 2.56 ± 0.452 0.910
%  Diameter stenosis 15.0 ± 9.54 13.4 ± 9.38 0.394
Reference diameter (mm) 3.02 ± 0.501 3.00 ± 0.559 0.843
Follow-up
MLD  (mm)  0.879 ± 0.523 2.52 ± 0.557 <0.001
%  Diameter stenosis 70.4 ± 16.7 20.1 ± 9.89 <0.001
Reference diameter (mm) 2.90 ± 0.438 3.15 ± 0.567 <0.01
Lesion length (mm) 8.30 ± 3.47 5.30 ± 3.75 <0.001
Acute gain (mm) 2.45 ± 0.525 2.25 ± 0.610 0.061
Late luminal loss (mm) 1.67 ± 0.579 0.058 ± 0.434 <0.001
Medication at discharge
-Blocker (%) 96.4 83.1 0.065
ACE-I/ARB (%) 89.3 93.0 0.480
Statin (%) 96.4 92.6 0.449
Binary restenosis (%) 100.0 0.0 <0.001
Follow-up %DS ≥ 70 (%) 42.9 0 <0.001
TLR  (%) 89.3 3.3 <0.001
Angiographic follow-up
duration (days)
328± 126 443± 221 <0.001
Variables related to patients, clinical condition, lesions, and procedure, and the
angiographic outcomes are shown. Deﬁnitions of abbreviations are provided in the
text.
Table 4
Predictors of binary restenosis.
Odds ratio 95% CI p-Value
Lower
limb
Upper
limb
PES 3.892 1.470 10.30 <0.01
Length of stent 1.048 0.991 1.108 0.102
Calciﬁcation 2.301 0.479 11.05 0.298
Pre-procedure %
diameter stenosis
1.049 0.877 1.255 0.600
Number of stents 1.225 0.289 5.185 0.783
First TIMI-grade 2–3
ﬂow
1.165 0.141 9.607 0.888
Pre-procedure MLD  0.751 0.002 360.1 0.928ngiographic outcomes are shown. Deﬁnitions of abbreviations are provided in the
ext.
.6. Individual predictors of binary restenosis after treatment
ith PES or SES for STEMI presenting within 48 h of onset
In a univariate analysis, in the PES group, the percentage of dia-
etes (61.9%), ﬁrst TIMI-grade 2–3 ﬂow (14.3%), the mean number
f stents (2.05 ± 0.865), the mean length of stents (50.7 ± 20.3 mm),
re-procedural MLD  (0.098 ± 0.257 mm),  and pre-procedural %DS
96.4 ± 9.8) in the binary restenosis (n = 21) group were signiﬁ-
antly different from those without binary restenosis (38.2%, 39.2%,
.39 ± 0.616, 33.3 ± 15.2 mm,  0.382 ± 0.491 mm,  and 86.7 ± 16.1)
n = 102) (p < 0.05, <0.05, <0.001, <0.001, <0.001, and <0.001, respec-
ively).
In the SES group, the percentage of calciﬁcation (14.3%), the
ean number of stents (1.86 ± 0.69), the mean length of stents
51.3 ± 21.9 mm),  and IVUS use (71.4%) in the binary resteno-
is (n = 7) group were signiﬁcantly different from those (1.4%,
.29 ± 0.52, 31.9 ± 14.0 mm,  and 99.3%) without binary restenosis
n = 140) (p < 0.05, <0.05, <0.05, and <0.001, respectively).
Predictors of binary restenosis analyzed using logistic regression analysis are shown.
PES  was  an independent predictor of binary restenosis. Deﬁnitions of abbreviations
are  provided in the text.
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Table 5
Predictors of binary restenosis after treatment with (A) PES and (B) SES.
Odds ratio 95% CI p-Value
Lower
limb
Upper
limb
(A) PES
Diabetes 2.384 0.795 7.15 0.121
Length of stent 1.030 0.965 1.100 0.377
Pre-procedure %
diameter stenosis
1.090 0.838 1.419 0.521
Number of stents 1.651 0.313 8.715 0.555
First TIMI-grade 2–3 ﬂow 1.804 0.073 44.60 0.719
Acute gain 1.107 0.309 3.966 0.876
Pre-procedure MLD 1.217 0.000 11167 0.966
(B) SES
Calciﬁcation 28.54 1.609 505.9 0.022
IVUS use 0.048 0.003 0.901 0.042
Length of stent 1.143 0.977 1.337 0.094
Number of stents 0.082 0.001 6.437 0.261
Predictors of binary restenosis analyzed using logistic regression analysis are shown
respectively in (A) PES and (B) SES groups. In the PES groups, there were no signif-
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lcant predictors of binary restenosis. In the SES groups, 2 variables were predictors
f binary restenosis. Deﬁnitions of abbreviations are provided in the text.
Table 5 shows the predictors of binary restenosis after treatment
ith (A) PES and (B) SES, which were identiﬁed using a logistic
egression analysis. In the multivariate analysis in (A), there was  no
igniﬁcant predictor of binary restenosis. In (B), both calciﬁcation
nd IVUS use were signiﬁcant predictors of binary restenosis after
reatment with SES.
. Discussion
This study found favorable post-discharge clinical outcomes
mong Japanese patients with STEMI treated with either PES or SES
ithin 48 h of onset. Speciﬁcally, with a mean follow-up period of
ore than 1100 days, the cardiac outcomes were similar to the val-
es without deﬁnite ST [3] (Table 1). Thus, this study conﬁrmed
he mid-term safety of SES for STEMI patients in a clinical set-
ing in Japan [1,2] and provided the ﬁrst demonstration for that
f PES. In contrast to the patients selected for previous prospective
andomized studies [12–14],  the present study included high-risk
atients with complex lesion-related cardiac events, ST events,
nd binary restenosis, such as those with Killip 3–4 classiﬁcations
15], bifurcation [16], calciﬁcation [17], thrombus lesions [18], and
onger stents [19] (Table 1). In addition, our study included patients
ho did not use glycoprotein IIb/IIIa inhibitors [20], up to 40%
iabetic patients [21], and a relatively high percentage of cardiac
ysfunction [22], factors that are representative of the daily practice
nvironment in Japan. Thus, we demonstrated the mid-term safety
f primary stenting using ﬁrst-generation DESs (SES and PES) for
TEMI patients presenting within 12 h of onset in Japan [1,2] and the
easibility of late reperfusion for STEMI patients treated 12–48 h of
nset in a daily practice environment. Further long-term observa-
ion should be continued to clarify the safety and efﬁcacy of primary
tenting using DES for STEMI patients in Japan [8].
The present study found that PES had inferior angiographic out-
omes compared to SES in STEMI patients (Tables 2 and 4). The
agnitude of late luminal loss in the PES group was  approximately
 times greater than that in the SES group, although the peripro-
edural QCA data did not signiﬁcantly differ (Table 2). In addition,
he risk for binary restenosis was approximately 4 times higher in
hose treated with PES (Table 4). This is consistent with a report
howing that SES had superior angiographic outcomes than PES
n STEMI patients [23]. Additional reports have shown statisti-
al equivalency in terms of binary restenosis and clinical target
esion revascularization between PES and SES for the treatment ofiology 60 (2012) 174–179
de novo stable lesions [24,25]. This intergroup discrepancy in the
angiographic efﬁcacy for de novo stable lesions and causal lesions
of STEMI may  be a result of differences in the stents’ properties.
First, sirolimus has a potent anti-restenotic effect for biologically
active lesions, such as the causal lesion of STEMI. Second, SES uses
a closed-cell based platform, allowing better diffusion of the drug
into the remodeling vessel compared to the open-cell based plat-
form of PES [24,26]. Although our multivariate analysis did not
identify signiﬁcant predictors of binary in-stent restenosis using
PES, PES was  disadvantageous for low pre-procedural TIMI-ﬂow,
high pre-procedural %DS, and low MLD  at primary reperfusion ther-
apy [Table 5(A)]. The present study indicates that SES is preferred
for primary stenting of STEMI patients compared to PES, except for
lesions with severe calciﬁcation and in cases where IVUS cannot
be used [Table 5(B)]. Thus, the disadvantages of ﬁrst-generation
DESs (SES and PES) for primary PCI of STEMI patients need to be
examined in the second-generation DESs.
The present study had several limitations. First, this was a
retrospective, non-randomized, and single-center analysis. A few
variables, such as LAD and RCA lesions, left ventricular dysfunction,
thrombus, and number of stents, signiﬁcantly differed between the
PES group and the SES group (Table 1). However, none of these vari-
ables was  related to safety or efﬁcacy endpoints (Table 4). Second,
although this cohort included late-reperfused STEMI patients, who
comprised approximately 15% of the group (Table 1), the safety
of late reperfusion should be conﬁrmed in a larger cohort. Third,
the duration of dual antiplatelet therapy was  based on the doctor’s
judgment according to a recent report [27]. The number of patients
that discontinued medical therapy, including dual antiplatelet ther-
apy, was not fully examined. However, there was no increase in the
number of post-discharge events or deﬁnite ST events (Table 1).
Fourth, other consistent predictors for cardiac events in STEMI
patients, such as renal dysfunction and anemia, were not fully
assessed.
5. Conclusions
The mid-term (mean interval, 1100–1200 days) safety of PES
for Japanese STEMI patients that presented within 48 h of onset in
a clinical practice setting was favorable, with a survival rate sta-
tistically equivalent to that of SES. However, PES was consistently
inferior to SES in the angiographic outcomes of STEMI cases.
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